Get started
Work

Outcomes and Risks of Allogeneic Hematopoietic Stem Cell Transplant for Hematological Malignancies in Patients with HIV Infection

Year: 2018
Type: article
Abstract: Background: Currently, 37 million people live with HIV. These patients are at a high risk of developing hematological malignancies (HM). Allo-HSCT is a potentially curative therapy for HM. Many uncertainties exist for HSCT in HIV patients, including donor selection, conditioning regimens, risk for GVHD and outcomes.
DOI: 10.1016/j.bbmt.2017.12.405
Authors: Shukaib Arslan, Nathan W. Cummins, Stacey A. Rizza, Andrew D. Badley, Mark R. Litzow, Willis H. Navarro, Shahrukh K. Hashmi
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W4240765674
FWCI:
Cites:
Cited by:
Related to: 10